Loading clinical trials...

Circulating MrgD in Pulmonary Hypertension | Clinical Trials | Clareo Health

RECRUITING

Circulating MrgD in Pulmonary Hypertension

Circulating MrgD Change in Patients With Pulmonary Hypertension

NCT06365372•Qilu Hospital of Shandong University

Summary

The aim of the study is to observe the change of the circulating MrgD level in patients with pulmonary hypertension compared with subjects without pulmonary hypertension.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•1. Male or female aged ≥18 years
•2. Right heart catheterisation to check the mean pulmonary artery pressure (mPAP) ≥25mmHg
•3. The patient is willing and able to provide written informed consent.
•1. Male or female aged ≥18 years
•2. No evidence of pulmonary hypertension on echocardiography or mean pulmonary artery pressure (mPAP) \< 25 mmHg on right heart catheterization, and no evidence of clinically relevant heart disease
•3. No evidence of clinically relevant pulmonary disease

Exclusion Criteria

•1. Age less than 18 years old
•2. Mean pulmonary artery pressure (mPAP) \<25mmHg
•3. Unable to provide informed written consent for participation in the study
•4. Renal insufficiency
•5. Liver insufficiency
•6. Malignant tumor
•7. Active infection
•8. Pregnancy
•1. Age less than 18 years old
•2. Mean pulmonary artery pressure (mPAP) ≥25mmHg
+7 more criteria

Locations (1)

Qilu Hospital of Shandong University

Jinan, Shandong, China

Key Dates

Start Date

April 10, 2024

Primary Completion Date

May 10, 2024

Completion Date

June 1, 2024

Last Updated

April 15, 2024

Enrollment

ESTIMATED participants

Conditions

Pulmonary Hypertension

Interventions

Western blot

DIAGNOSTIC_TEST

Contacts

Panpan Hao, MD

CONTACT

8618560086593 panda.how@sdu.edu.cn

A Study to Learn About the Study Medicine (Called PF-07868489) in People With Pulmonary Arterial Hypertension Who Have Previously Participated in a Clinical Study With PF-07868489

NCT07073820

Pulmonary Hypertension

View study

RECRUITINGPHASE1

Preliminary Human Trials of F230 Tablets

NCT06899815

Pulmonary Hypertension

View study

RECRUITINGPHASE2/PHASE3

Sildinafil in Pulmonary Hypertension-Rheumatic Chronic Valvular Disease(RCT)

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: April 15, 2024Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Circulating MrgD in Pulmonary Hypertension

Inclusion Criteria

Exclusion Criteria

A Study to Learn About the Study Medicine (Called PF-07868489) in People With Pulmonary Arterial Hypertension Who Have Previously Participated in a Clinical Study With PF-07868489

Preliminary Human Trials of F230 Tablets

Sildinafil in Pulmonary Hypertension-Rheumatic Chronic Valvular Disease(RCT)

Prospective Evaluation of AI-ECG for SHD Detection

Pulmonary Hypertension in Left Heart Disease

CD19-BCMA CART Cell Therapy for Refractory SLE-LN, SSc, and pSS-PAH